Fayez Sarofim & Co’s Novartis NVS Stock Holding History

Fayez Sarofim & Co’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.41M	Buy	28,162 +300	+1%	+$45K	0.01%	121
2026 Q1	$4.26M	Sell	27,862 -390	-1%	-$59.8K	0.01%	121
2025 Q4	$3.9M	Buy	28,252 +300	+1%	+$39.3K	0.01%	130
2025 Q3	$3.58M	Sell	27,952 -184	-0.7%	-$22.5K	0.01%	134
2025 Q2	$3.4M	Sell	28,136 -800	-3%	-$90.2K	0.01%	135
2025 Q1	$3.23M	Sell	28,936 -5,650	-16%	-$601K	0.01%	136
2024 Q4	$3.37M	Sell	34,586 -5,654	-14%	-$603K	0.01%	135
2024 Q3	$4.63M	Buy	40,240 +250	+0.6%	+$28.4K	0.01%	119
2024 Q2	$4.26M	Sell	39,990 -9,410	-19%	-$945K	0.01%	121
2024 Q1	$4.78M	Sell	49,400 -2,075	-4%	-$213K	0.01%	117
2023 Q4	$5.2M	Sell	51,475 -12,865	-20%	-$1.24M	0.02%	110
2023 Q3	$6.55M	Sell	64,340 -53,160	-45%	-$5.4M	0.02%	101
2023 Q2	$11.9M	Sell	117,500 -118,745	-50%	-$11.9M	0.04%	86
2023 Q1	$21.7M	Sell	236,245 -110,285	-32%	-$9.63M	0.08%	81
2022 Q4	$31.4M	Sell	346,530 -31,315	-8%	-$2.64M	0.12%	75
2022 Q3	$28.7M	Sell	377,845 -26,486	-7%	-$2.2M	0.11%	74
2022 Q2	$34.2M	Sell	404,331 -11,025	-3%	-$967K	0.12%	76
2022 Q1	$36.4M	Buy	415,356 +4,156	+1%	+$360K	0.12%	77
2021 Q4	$36M	Buy	411,200 +9,046	+2%	+$751K	0.11%	81
2021 Q3	$32.9M	Sell	402,154 -12,117	-3%	-$1.09M	0.11%	80
2021 Q2	$37.8M	Sell	414,271 -12,954	-3%	-$1.15M	0.13%	77
2021 Q1	$36.5M	Buy	427,225 +3,370	+0.8%	+$302K	0.13%	74
2020 Q4	$40M	Sell	423,855 -1,700	-0.4%	-$149K	0.15%	69
2020 Q3	$37M	Sell	425,555 -11,750	-3%	-$1.02M	0.16%	69
2020 Q2	$38.2M	Buy	437,305 +100	+0%	+$8.63K	0.18%	66
2020 Q1	$36M	Sell	437,205 -3,593	-0.8%	-$321K	0.22%	60
2019 Q4	$41.7M	Sell	440,798 -7,167	-2%	-$643K	0.2%	64
2019 Q3	$38.9M	Sell	447,965 -5,300	-1%	-$476K	0.2%	65
2019 Q2	$41.4M	Sell	453,265 -46,787	-9%	-$3.96M	0.21%	64
2019 Q1	$43.1M	Sell	500,052 -26,746	-5%	-$2.15M	0.23%	64
2018 Q4	$40.5M	Sell	526,798 -66,850	-11%	-$5.2M	0.24%	66
2018 Q3	$45.8M	Sell	593,648 -366,404	-38%	-$27.1M	0.24%	66
2018 Q2	$65M	Sell	960,052 -510,887	-35%	-$35.3M	0.35%	61
2018 Q1	$107M	Sell	1,470,939 -36,737	-2%	-$2.8M	0.58%	44
2017 Q4	$113M	Sell	1,507,676 -99,639	-6%	-$7.52M	0.59%	44
2017 Q3	$124M	Sell	1,607,315 -4,516	-0.3%	-$341K	0.65%	42
2017 Q2	$121M	Sell	1,611,831 -37,841	-2%	-$2.68M	0.64%	41
2017 Q1	$110M	Sell	1,649,672 -18,971	-1%	-$1.26M	0.6%	45
2016 Q4	$109M	Sell	1,668,643 -68,138	-4%	-$4.42M	0.6%	47
2016 Q3	$123M	Sell	1,736,781 -56,875	-3%	-$4.14M	0.67%	45
2016 Q2	$133M	Buy	1,793,656 +86,822	+5%	+$6M	0.73%	43
2016 Q1	$111M	Buy	1,706,834 +21,936	+1%	+$1.49M	0.63%	46
2015 Q4	$130M	Buy	1,684,898 +2,066	+0.1%	+$164K	0.75%	42
2015 Q3	$139M	Buy	1,682,832 +91,711	+6%	+$8.16M	0.8%	40
2015 Q2	$140M	Sell	1,591,121 -99,370	-6%	-$9.12M	0.71%	50
2015 Q1	$150M	Buy	1,690,491 +176,461	+12%	+$15.7M	0.73%	48
2014 Q4	$126M	Buy	1,514,030 +232,871	+18%	+$19.3M	0.6%	54
2014 Q3	$108M	Buy	1,281,159 +27,743	+2%	+$2.24M	0.5%	57
2014 Q2	$102M	Buy	1,253,416 +19,227	+2%	+$1.51M	0.47%	59
2014 Q1	$93.9M	Sell	1,234,189 -9,379	-0.8%	-$683K	0.45%	59
2013 Q4	$89.6M	Buy	+1,243,568	New	+$86.4M	0.42%	58
2013 Q2	$57.4M	Buy	+905,719	New	+$58.9M	0.29%	61

Other funds holding NVS

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Fayez Sarofim & Co's NVS Position: Q2 2026 in Review

Fayez Sarofim & Co increased its Novartis (NVS) stake by 1.1% in Q2 2026, buying an estimated $45K and bringing the position to 28,162 shares worth $4.41M. The position accounts for 0.01% of the portfolio, ranked #121.

Fayez Sarofim & Co first reported a position in NVS in Q2 2013 and has held it in 52 quarters since. The position peaked at $150M in Q1 2015. 1,612 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

Fayez Sarofim & Co held 28,162 shares of Novartis worth $4.41M as of Q2 2026.
Fayez Sarofim & Co bought 300 Novartis shares in Q2 2026, an estimated $45K.
Novartis made up 0.01% of Fayez Sarofim & Co's portfolio in Q2 2026, its #121 holding.
Fayez Sarofim & Co first reported a position in Novartis in Q2 2013 and has held it in 52 quarters since.
Fayez Sarofim & Co's Novartis position peaked at $150M in Q1 2015.
1,612 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Fayez Sarofim & Co's 13F filing for Q2 2026, filed 17 Aug 2026.